Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Hypertrophic cardiomyopathy wikipedia , lookup
Coronary artery disease wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Myocardial infarction wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Cardiac arrest wikipedia , lookup
The Long QT Syndrome Overview and Management Edited by A.Kharazi M.D Cardiac electrophysiologist LQTS Outline • Background • Identification • Therapies Available • Current Management • Ongoing Research • Case Studies • Conclusions Long QT Syndrome Background and the Risk of Sudden Cardiac Death Sudden Cardiac Death (SCD) • Affects 350,000 - 400,000 each year in the US alone • Only 5% of victims survive • Causes of SCD may include structural heart disease or a genetic channelopathy • Recognition of risk factors can help identify those at risk of SCD Risk Factors for SCD in Young People • Structural congenital heart disease - before and after corrective surgery • Congenital anomalies of coronaries • Myocarditis • Hypertrophic and other cardiomyopathies • Wolff-Parkinson-White Syndrome • Long QT Syndrome LQTS: Historical Aspects 1957: 1st LQTS family reported 1963-1964: Romano-Ward Syndrome 1958-1970: 25 LQTS cases reported 1971: 1st LQTS Rx (left stellate ganglionectomy) 1979: LQTS Registry Started 1991-2001: 6 LQTS genes identified Long QT Syndrome • Genetic disorder (1:5,000-10,000) • ECG evidence: QTc interval prolonged • >440 ms in males • >450 ms in females • Hallmark arrhythmia: Torsade de pointes VT • Primary presenting symptom: Syncope • SCD in children or young adults LQTS: Identification LQTS: Identification of Risk • Most common presenting symptom: unexplained syncope. • Syncope on exertion in pediatric patients should be considered malignant until proven otherwise. • History & ECG: – Onset and offset of syncopal episode – Siblings, or family members with unexplained syncope or sudden death – Family history of “seizures” or congenital deafness – Prolonged QTc on ECG Syncope Slow Onset Slow Offset Abrupt Onset Abrupt Offset Hyperventilation Abrupt Onset Slow Offset Seizure disorder Hypoglycemia Obstructive Arrhythmic Vascular Aortic Stenosis, HCM, Myxoma Brady Tachy Vasovagal, Orthostatic Hypertension Causes of Arrhythmic Syncope • Very rapid VT or TdP, with hypotension • Atrial fibrillation or atrial flutter with very rapid ventricular response as in WPW • AV block • Sinus arrest Holter ECG Recording in LQTS Patient with Syncope (representative strips of ECG recording, part 1 of 2) Holter ECG Recording in LQTS Patient with Syncope (representative strips of ECG recording, part 2 of 2) LQTS: Clinical Features Symptoms ECG Signs • Syncope • Prolonged QTc • Seizures • Torsade de pointes • Sudden death • Palpitations or “chest pain” LQTS ECG Patterns Circ 1992;85[Suppl I]:I140-I144 Additional LQTS ECG Patterns Circ 1992;85[Suppl I]:I140-I144 What Should You do with the ECG? • Don’t rely on computer evaluation of ECG • Obtain an independent review of the ECG • Have an experienced cardiologist measure the QTc interval • If the ECG is suspicious for LQTS, refer the patient for cardiac evaluation LQTS: Diagnostic Criteria • ECG findings: QTc, TdP, notched T waves, slow heart rate for age • Clinical history: syncope, seizures, aborted cardiac arrest • Family history: family member with LQTS, unexplained SCD in a first-degree relative who was <55yrs of age Circ 1993;88:782-784 QTc Interval and Risk Risk for Cardiac Event 2.8 2.2 1.6 1.0 440 520 600 QTc AJC 1993;72:21B 680 LQTS: Who is at Risk for SCD? • Aborted cardiac arrest • Family history of unexplained sudden death • Syncope • Torsade de pointes • T-wave alternans • Prolonged QTc Probability of Cardiac Event in LQTS Probands Affected Undetermined Unaffected Circ 1991;84:1136-1144 Triggering Events for Syncope or SCD • 3 main factors contributing to syncope or SCD – Exercise (LQT1), especially swimming – Emotions or emotional stress (LQT2) – Events occurring during sleep or at rest, with or without arousal (LQT2 or LQT3) Circ 2001;103:89-95 Mayo Clin Proc. 1999;74:1088-1094 Occurrence of Gene-Specific Triggers 70 Exercise Emotional Stress Rest 62 Percent 60 50 43 40 30 39 29 26 19 20 13 10 13 3 0 LQT1 Circ 2001;103:89-95 LQT2 LQT3 Basis for the Long QT Syndrome JCE 1999;10:1664-1683 LQTS: Phenotype-Genotype Considerations • 6 genotypes; ~200 different mutations • Clinical differences among LQT1, LQT2, & LQT3 genotypes • Clinical variability within a genotype • Clinical variability among members of a family with the same gene mutation suggests presence of modifier genes T-wave Morphology in LQTS by Genotype Moss AJ, et al. Circulation 1995;92:2929-2934 Probability of a Cardiac Event No. of Subjects LQT1 group LQT2 group LQT3 group NEJM 1998;339:960-965 112 72 62 72 56 56 36 29 36 27 16 24 19 11 16 Therapies Available and Current Management Drugs in Long QT • Certain drugs may provoke life-threatening arrhythmias in LQTS patients – Examples: • Antiarrhythmic: procainamide, quinidine, amiodarone, sotalol, et al • Antihistamine: astemizole, terfenadine, et al • Antimicrobial/antifungal: thiomethoprim sulfa, erythromycin, ketoconazole, et al • Psychotropics: haloperidol, risperidone, thioridazine, tricyclics, et al • Other: epinephrine, diuretics, cisapride, bepridil, ketanserin, et al • Avoid nonessential OTC medications • For more information see: www.qtdrugs.org Current Treatments • Left stellate ganglionectomy (occasionally utilized in infants and patients refractory to other forms of therapy) • Beta blockers • Pacemakers • Implantable Cardioverter Defibrillators (ICDs) Management by Genotype • LQT1 and LQT2 benefit the most from ß-blocker therapy • The benefit of ß-blocker therapy is less clear in LQT3. • ICDs indicated: – if the patient presents as SCD survivor or aborted cardiac arrest – if ß-blockers are not effective in preventing cardiac events LQTS: Cardiac Events Before and After -blockers Probands (n=581) (n=288) 5.2 4.5 Risk exposure, yrs (pre- and post- B) Pre-B Pts with events Number events Events/pt Events/pt/year Circ 2000;101:616-623 AFM† Post- B Pre- B Post B 462 1671 3.0 194* 623* 1.1* 92 245 0.9 49* 138* 0.5* 1.0 0.3* 0.3 0.15* †Affected Family Member * P<0.01 vs. pre--blocker Efficacy of -blockers in LQTS • Significant reduction in frequency of syncopal events • Cardiac events continued to occur • May reduce the rate of SCD • Reductions in rate of cardiac events – 0.97±1.42 to 0.31±0.86 events/year in probands – 0.26±0.84 to 0.15 ±0.69 events/year in affected family members • P<0.001 Circ 2000;101:616-623 Probability of Cardiac Event Circ 2000;101:616-623 Cumulative Probability of LQTS- Related Death w/ ß-blockers Circ 2000;101:616-623 Limitations of -blockers in LQTS • SCD can occur despite Rx with -blockers • Long-term compliance with daily therapy is problematic • Usual side effects of -blockers ICD Experience in LQTS • An ICD is indicated for all patients with documented VT, VF or aborted cardiac arrest • Prevents SCD in patients with prior cardiac events • Provides a back-up for patients on -blocker therapy who continue to be symptomatic ICD Experience in LQTS N 88 Age at ICD, y 23±10 Female 71% QTc, sec 0.52±0.06 -B before/after ICD 82% / 89% ACA before/after ICD 48% / 4% Death after ICD 0 in 2.5yr (0.1-9.0yr) A.J. Moss; AHA Abstracts Online. 1999. Pacemaker Experience in LQTS • Reduces frequency of syncope in pts. with bradycardia-triggered events • Most useful when combined with -blocker therapy • Does not prevent SCD in long-term therapy • Appears most useful in patients with LQT3 and bradycardia Circ. 1999;100:2431-2436 Sinus rhythm NEJM 2000;342:398 Sinus rhythm Torsade de pointes NEJM 2000;342:398 Sinus rhythm Torsade de pointes Ventricular fibrillation and sinus rhythm NEJM 2000;342:398 Ongoing Research LQTS: Studies in Progress • LQTS Registry: risk-factor identification • Trigger factors • New gene identification – LQTx ? • Exercise stress testing for diagnosis and risk stratification • Modifier genes • Mutation-specific therapy Case Studies Case Study 1 • 13 year old male presents with syncope while swimming • QTc prolongation on ECG (>500ms) • Beta-blocker therapy initiated • No further cardiac events noted over 5 years • Can you consider withdrawing beta-blocker therapy? • Is an ICD indicated? Case Study 2 • Young male athlete diagnosed with LQTS • Beta-blockers prescribed • Patient stops drugs because he feels better without them • What should the physician do? Case Study 3 • 15 year old male • ECG as part of routine physical • QTc = 450ms • Asymptomatic • No family history • Question: Is this LQTS? Conclusions • Unexplained syncope with exertion in children and young adults should be considered serious until proven otherwise. • ECGs should be obtained on the patient and read by a cardiologist or pediatric cardiologist if patient is a child. • ECGs should be obtained on all immediate family members. • Referral to a cardiac specialist if suspicious for LQTS. Long QT Resources • Cardiac Arrhythmias Research and Education (CARE) Foundation: www.longqt.org • Cardiac Arrest Survivors Network (CASN): www.casn-network.org • International Registry for Drug-Induced Arrhythmias, including drugs to use with caution or avoid in Long QT patients: www.qtdrugs.org